S100A4 and cancer: The M2-like protumor phenotype of TAMs is reversible in most observed cancers.50 Metabolic reprogramming holds potential for modulating macrophage phenotypes and developing new therapeutic approaches.50 Our current analysis of clinical human cancer data showed greater expression of S100A4 and CD68 to be a strong predictor of poor prognosis for cancer patients.